Please Note: Due to volume considerations, not all questions can be answered. Questions most likely to be answered will be those of general interest to a broad group of visitors to this forum. Questions pertaining to a specific case; requests for diagnosis, medical advice, or second opinion; or requests for opinions about untested alternative therapies will generally not be answered.
|
 |
 |
New Regimen Side Effects
May 4, 2007
Hello Doctor,
I am 35 and live in holland. Discovered was HIV+ in 2002. I was recently diagnosed with drug resistance to Efavirenz and Lamivudine, my regimen consisted of Sustiva and combivir and worked perfectly for 4 years till recently due to some cuts offs I developped this resistance to both drugs. My Doctor wants to switch me to Viread, Reyataz, Norvir and wants me to continue taking combivir, he is saying that since the AZT is still working that I should continue and the lamivudine will be most probably more effective for the ''mutant'' chain of viruses?!! My concern is that I already suffered fat loss from my hands and legs and a little bit from my face but since I work out a lot and maintain a very healthy lifestyle, it doesn't show a lot but to me it is obvious and sometimes it causes me some anxiety (some self esteem issues). I also have some stubborn fat deposit around my belly which I am fighting with aerobics, L-carnitine and a low fat diet, results are ok but not satisfactory to my level. My concern is with this new regimen and the reputation that some of these drugs I am taking would increase fat deposits around my belly, the high triglycerides in my blood and the ''yellow eyes'' syndrome. Can you please shed some light on the side effects of this regimen?
Thank you for your answer and all the help you are providing.
|
 |
 |
Advertisement
Response from Dr. Henry

Continuing the AZT could contribute to fat loss so sometimes a aough choice needs to be made. Often switching the AZT to tenofovir may help the fat issue some. Tenofovir can lower the atazanavir levels though with ritonavir boosting the levels are usually good enough. Using Kaletra (lopinavior/ritonavir) or ritonavir/Lexiva with Truvada (tenofovir + FTC) avoids any negative drug interactions from the ART perspective. Much of the fat related problems comes from the NRTI backbone with Truvada (or Epzicom= 3TC + abacavir) usually being more fat friendly. Another PI option is either ritonavir boosted daurunavir or saquinavir depending on what is available/approved in Holland. Often the first order of business is get suppressed again and then work with the regimen to try to make it as well tolerated and fat friendly as possible.. KH
Want to read more questions and answers on this subject? Our experts have answered many similar questions!
|
|
 |
 Please remember that this forum is designed for educational purposes only, and experts are not engaged through this
forum in rendering legal or medical advice or professional services. Experts appearing on this page are independent and are solely responsible
for editing and fact-checking their material. Neither The Body nor any sponsor is the publisher or speaker of posted visitors' questions or the experts' material.
Questions and messages posted to this forum are not statements of advice, opinion, or information of The Body, Body Health Resources Corporation or any sponsor of this
forum. While neither The Body nor Body Health Resources Corporation regularly reviews posted content, we reserve the right to delete, move, or
edit postings if we deem it appropriate under the circumstances. Visitors submitting questions remain solely responsible for the content of their
messages.
Information provided by experts is general only and should not be used for diagnosing or treating a health problem or a disease, or relied upon as
legal or other professional advice. This information is not a substitute for professional advice or care. If you have or suspect you may have a
health or legal problem, you should consult your own health care provider or your attorney.
Copyright notice.
|
|
Advertisement
|
|